Lentiviral gene therapy for X-linked chronic granulomatous disease

Area of Science:

• Hematology
• Immunology
• Gene Therapy

Background:

• Chronic granulomatous disease (CGD) is a rare inherited disorder affecting phagocytic cells.
• X-linked CGD (X-CGD) is the most common form, leading to severe immune deficiencies.
• Current treatments are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To assess the safety and efficacy of ex vivo autologous CD34+ hematopoietic stem and progenitor cell-based lentiviral gene therapy in X-CGD patients.
• To evaluate biochemical and functional reconstitution, augmented immunity, and hematopoietic stem cell engraftment at 12 months post-treatment.

Main Methods:

• Nine severely affected X-CGD patients received myeloablative conditioning followed by autologous lentiviral gene therapy.
• Safety, vector copy numbers, neutrophil oxidase function, and clinical outcomes were monitored.
• Assessments included transduction, engraftment, and immune reconstitution against bacterial and fungal infections.

Main Results:

• Six of seven surviving patients showed stable vector copy numbers and significant persistence of oxidase-positive neutrophils at 12 months.
• Surviving patients experienced no new CGD-related infections, with six discontinuing antibiotic prophylaxis.
• No evidence of clonal dysregulation or transgene silencing was observed in treated patients.

Conclusions:

• Autologous lentiviral gene therapy is a safe and promising approach for treating X-linked chronic granulomatous disease.
• The treatment led to significant functional immune reconstitution and reduced infection rates in surviving patients.
• This gene therapy strategy offers a potential curative option for individuals with severe X-CGD.